Intimation of demise of Independent Director.

Management Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹51.15

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%-5.6% vs market

IT Enabled Services peers, median of 57sector-0.5%-5.4% vs sector

On the reaction day the stock moved 5.6 pts less than Nifty Microcap 250 and 5.4 pts less than its IT Enabled Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9-0.3-5.6-0.5-5.4

Next day

+3.5+0.2+3.3-0.4+4.0

+3.6+0.8+2.8+0.3+3.3

-1.6+0.7-2.2-0.3-1.3

—+2.1—+0.9—

—+2.8—+2.7—

-4.2+1.7-5.9+3.6-7.8

15d

—-0.4—+0.5—

-9.7+2.9-12.6+2.3-12.0

+5.6+0.8+4.8-1.2+6.7

—+0.9—-1.4—

UpDownMarket · Nifty Microcap 250Sector · IT Enabled Services peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Euphoria Infotech (India) Ltd has informed the stock exchange about the sad demise of Mr. Sriyans Lunia, an Independent Director on the Board, who passed away on May 31, 2025. Mr. Lunia had been associated with the company since May 5, 2023, and had served on the Board and its Committees. The company expressed condolences to his family and acknowledged his contributions. The intimation was made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Likely market impact

The company now has a vacancy on its Board as an Independent Director, which it will need to fill within the timelines prescribed under SEBI rules and the Companies Act to maintain the required composition. This is a routine governance disclosure and is unlikely to materially affect the stock price.